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Peritonitis remains a common clinical problem for patients
on peritoneal dialysis (PD). There are, however, retrospective
studies with historical controls that suggest that
biocompatible PD solutions may reduce the rates of
peritonitis. We conducted a randomized controlled study
comparing the use of biocompatible and conventional
solutions, accumulating over 7000 patient-months
experience. We included peritonitis episodes from patients
who discontinued PD during the follow-up period. The study
was powered to detect a reduction in the peritonitis rate of
over half in the 267 randomized patients in demographically
similar groups. There were no intergroup differences in PD
technique survival irrespective of whether the outcome was
censored for death. Peritonitis-free survival was 26.7 months
using conventional compared to 23.1 months using
biocompatible PD solutions. The peritonitis rates were also
not statistically different when measured in patient-months.
Thus, despite the finding of non-randomized studies
suggesting benefits of the biocompatible PD solutions, we
could not detect any clinically significant advantages in terms
of technique survival or peritonitis. Although our study is the
largest randomized study comparing different PD solutions
to date, we do not exclude the possibility that our results are
a consequence of the lack of statistical power. Meta-analysis
of randomized control trials in this field is essential.
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It has been suggested that the bio-incompatible nature of con-
ventional peritoneal dialysis (PD) solutions contributes to the
structural peritoneal membrane changes that lead to deteriora-
tion in solute transport characteristics and loss of ultrafiltra-
tion.1,2 The in vitro use of neutral-pH, low-glucose degradation
product solutions (‘biocompatible’ solutions)3 have also been
shown to improve function and viability of the peritoneal
membrane4,5 and other cells associated with host defense.6
It is on this background that data from retrospective
studies comparing patients using ‘conventional’ PD solutions
vs ‘biocompatible’ solutions were received with great
excitement. Peritonitis rates were reported to be lower7,8
and survival higher9 in patients using the biocompatible
solutions. Unfortunately, results of randomized controlled
trials that have reported on peritonitis rates have been small
and were not powered to look at these endpoints.
We have conducted a large prospective randomized
controlled open-label trial of incident patients starting PD.
We have already reported the results of the primary endpoint:
changes in residual renal function (assessed by 24-hour
urine collection) over a 1-year follow-up.10 The secondary
endpoints for this study included:
K Peritonitis rate
K PD technique survival (censored for transplantation)
Enrolment into the study continued to achieve sufficient
power to report whether there are any clinically or
statistically significant differences in peritonitis rates with
the use of biocompatible solutions. We now report our long-
term findings, which are probably the largest single-center
study of this type (267 randomized patients), with regard
to these secondary endpoints.
RESULTS
Study population
During the recruitment period from 1 January 2004 to 1 June
2008, 267 patients newly starting PD at our institution gave
informed consent to participate in our study. There were 139
patients randomized to receive biocompatible solutions (52%
on continuous ambulatory peritoneal dialysis (CAPD)) and
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128 randomized to receive conventional solutions (58% on
CAPD). Of the CAPD patients, 19 used StaySafe Balance and
17 used StaySafe Standard solutions (Fresenius Medical Care,
Bad Humburg, Germany). All other CAPD and all automated
peritoneal dialysis (APD) patients used solutions (Dianeal or
Physioneal) supplied by Baxter Healthcare (Morthants, UK).
The demographics of these patients (Table 1) showed no
significant statistical differences for age, sex, proportion of
patients with diabetes mellitus, previous requirement for
hemodialysis, and ethnicity.
There were five patients who crossed over treatments for
clinical reasons (four from conventional to biocompatible
for drain-in pain and one switched to conventional solutions
for ease of use). Results described are on an intention-to-treat
basis, although results of a ‘per-protocol’ analysis would have
been almost identical.
PD technique failure
We performed two analyses. In the first technique, failure was
defined as either death or transfer to hemodialysis (data
censored for transplantation, renal recovery, and transfer of
patients to other PD units), whereas in the second technique,
failure was also censored for death. The survival curves are
shown in Figures 1 and 2. The median PD technique survival
(not censored for death) for patients using biocompatible
solutions was 48.0 months and was 39.1 months for the
conventional PD solution group, but this was not statistically
different (hazard ratio 0.92, 95% CI: 0.63–1.35).
Peritonitis rate
The peritonitis-free survival of patients (censored for death,
transfer to hemodialysis or other PD units, renal recovery,
and transplantation) is shown in Figure 3. The median
peritonitis-free survival for the patients randomized to
conventional solutions was 26.7 months compared with
23.1 for the biocompatible solutions (hazard ratio 0.96, 95%
CI: 0.69–1.34), P¼ 0.82 by log-rank Mantel–Cox test.
There were 227 peritonitis episodes suffered by the
patients, with an at-risk period of 7408 patient-months.
This gave a peritonitis rate of 1:32.6 patient-months. The
Table 1 | Demographic and baseline details of study patients
Study recruitment
Biocompatible Standard P-value
Number 139 128
Age (mean/s.d.), years 53.0 (1.4) 54.5 (1.3) 0.44
% On CAPD as initial modality 58 52 0.39
Sex (% males) 68 61 0.25
% Diabetes mellitus 32 34 0.74
Ethnicity (% Caucasian) 48 46 0.73
Cause of ESRF (%)
Diabetic nephropathy 22 27 0.22
Chronic GN 17 22
Chronic pyelo/intersitial nephritis 8 11
APKD 6 5
Hypertension 10 13
Others 6 9
Unknown 35 21
Abbreviations: AKPD, adult polycystic kidney disease; CAPD, continuous ambulatory
peritoneal dialysis; ESRF, end-stage renal failure; GN, glomerulonephritis.
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Figure 1 |Peritoneal dialysis (PD) technique survival (censored
for transplantation and transfer out of unit).
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Figure 2 |Peritoneal dialysis (PD) technique survival (censored
for death, transplantation, and transfer out of unit).
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Figure 3 |Peritoneal dialysis (PD) peritonitis-free survival of
patients remaining on PD.
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peritonitis rate for the patients treated with conventional
solutions was 1:31.5 vs 1:34.7 in the biocompatible group
(P¼ 0.61 by Pearson uncorrected w2).
The organisms causing the peritonitis episodes are listed
in Table 2. Overall, Gram-positive organisms were identified
as the causative organism in 54% cases of peritonitis, whereas
Gram-negative and ‘culture-negative’ peritonitis occurred
with a frequency of 20% and 24%, respectively. There was no
difference in the distribution of the causative organisms
between the two groups (P¼ 0.11 by w2).
DISCUSSION
Furkert et al.8 performed a retrospective study of 120 patients
divided into two cohorts (patients who started PD before and
after the year 2000) and suggested that the improvement
in peritonitis rate after 2000 was attributed to the use of
biocompatible solutions. It is disappointing to find that a
randomized study of more than double their number of
patients failed to confirm their findings. There are many
reasons as to why peritonitis rates may fall over a 15-year
period; improved patient education and changes in the
patients selected for PD are two obvious examples. At best,
retrospective studies can only generate a hypothesis, which is
to be tested by randomized controlled studies. Our results
unfortunately appear to refute the hypothesis that improved
‘biocompatible’ solutions can lead to lower peritonitis rates
for patients on PD.
How do our results compare with other randomized trials
comparing ‘conventional’ vs ‘biocompatible’ PD solutions?
Other studies thus far have generally been designed to study
the effect on residual renal function, and have short follow-
up. Therefore, these studies have been underpowered to
determine whether the in vitro benefits on enhanced
leukocyte functioning6,11 can translate into a clinical benefit.
Table 2 | Number and causes of peritonitis
Conventional Biocompatible P-value
Number of patients 128 139
Total duration of PD (at risk period) 3465 3942
Number Rate (pt-mths) Number Rate (pt-mths)
All peritonitis 110 1:31.5 117 1:33.7 0.61
Break down of organism Number % Number %
Gram positive 51 46 72 62 0.10
Gram negative 24 22 22 19
Culture negative 32 29 22 19
Fungal 3 3 1 1
Abbreviations: PD, peritoneal dialysis; pt-mths, patient-months.
Table 3 | List of trials randomizing patients to ‘Biocompatible’ or ‘Conventional’ peritoneal dialysis solutions
Author Type of study and solution Duration Peritonitis
Tranaeus (2000)12 RCT: Physioneal vs Dianeal, 106 prevalent patients 6 months 1:26 pt-months Biocompatible
1:23 pt-months Controla
Williams (2004)13 RXCT: Balance vs StaySafe, 71 prevalent patients 12 weeks at phase Not reported
Le Poole et al. (2005)14 RCT: Combination of Nutrineal, Extraneal and
Physioneal vs Dianeal, 63 incident patients
30 weeks Not reported
Montenegro et al. (2006)15 Non-randomized: BicaVera vs StaySafe, 36 prevalent
patients
12 months Not reported
Szeto et al. (2007)16 RCT: Balance vs StaySafe, 50 incident patients 12 months No difference in peritonitis-free survival
87.5% Biocompatible
75.3% Control
Choi et al. (2008)17 RCT: Balance vs StaySafe, 104 prevalent patients 12 months Drop out due to peritonitis:
3/51 Biocompatible
2/53 Control
Kim et al. (2009)18 RCT: Balance vs StaySafe, 91 incident patients 12 months No difference in peritonitis-free survival
BUT, overall peritonitis rate:
1:49.2 pt-months Biocompatible
1:131.5 pt-months Control Po0.04 by Pearson
uncorrected w2 test
Weiss et al. (2009)19 RXCT: BicaVera vs StaySafe, 55 prevalent patients 12 weeks at phase Not reported
Haag-Weber et al. (2010)20 RCT: Gambrosol Trio vs Gambrosol/Staysafe/
Dianeal, 80 prevalent patients
18 months No difference:
1:36.4 pt-months Biocompatible
1:39.7 pt-months Control
Abbreviation: pt-months, patient-months; RCT, randomized controlled trial; RXCT, randomized crossover clinical trial.
aBut 57/88 patients continued in extension (unequal proportions continued) and after 12 months, there was statistical difference in peritonitis: 1:51 Biocompatible vs 1:19
Control (Po0.05).
988 Kidney International (2011) 80, 986–991
or ig ina l a r t i c l e S Srivastava et al.: Biocompatible PD solutions and peritonitis
Listed in Table 3 are the published clinical trials comparing
biocompatible solutions with conventional solutions, and
four papers provided information about peritonitis rates
during the trials. The peritonitis rates in the Haag–Weber
study20 were similar to those in our study and there was no
statistically significant difference. Similarly, the study by
Szeto et al.16 reported that the 1-year PD peritonitis-free
survival of patients in their study was also similar to that in
our study, and again there was no statistical difference.
Interestingly, the paper by Kim et al.18 reported that the
peritonitis rates in the biocompatible group was 14 in 684
patient-months vs 6 in 789 patient-months in the control
group. These rates are remarkably low when compared with
other quoted peritonitis rates in the literature. Although it
was not commented at the time, using Pearson’s uncorrected
w2 test, the different peritonitis rates would have reached a
statistical significance level of Po0.04. Contrary results were
reported by Traneus et al.12 who showed that in an extension
study (but not in the original study) the peritonitis rates were
lower in the biocompatible group (1:51 patient-months)
when compared with the control group (1:19 patient-
months). However, the authors confirmed that there were
differences in the proportions of patients who proceeded into
the extension study and that the results may have been
influenced by withdrawal bias by the investigators/partici-
pants. It is against this background that we hope our data will
provide a more definitive answer to the question. Our study
reports the results of prolonged follow-up of the largest
randomized study in this field; however, we cannot find
evidence to support this hypothesis.
It is also disappointing to find that we did not observe any
improvement in PD technique survival despite non-random-
ized retrospective and prospective studies from South
Korea9,21 This should not be unexpected as our renal
transplantation rates were high, and therefore even a study
of over 250 patients would be expected to be underpowered.
Altogether, over 1200 patients were in the retrospective
Korean observational study,9 despite which statistical sig-
nificance was only just achieved (the relative risk of death for
the biocompatible group was 0.75, Po0.05). Similarly, large
numbers of patients (extracted from a database of 4000
patients) were required in a later non-randomized study by
the same authors21 in order for the relative risk of death of
0.61 to be statistically significant (this analysis was performed
on an ‘as-treated’ analysis rather than an ‘intention-to-treat’
analysis, which might have permitted bias to be introduced).
Our failure to show a significant PD technique survival is
therefore not unexpected and may represent a Type II
statistical error.
It is also possible that biocompatible solutions do reduce
peritonitis rates, but the impact is not as great as first
suggested in the literature. As is common when planning a
study, we powered our study at 90% to detect a 50% reduction
in peritonitis rates. However, the actual peritonitis rate of the
control group was lower than expected, and in fact recalcula-
tion showed that our study was powered at 95% to detect a
40% reduction of peritonitis rates. Nevertheless, our study
cannot exclude the possibility that biocompatible solutions
may have clinical benefits (there is a 20% chance that our
study would not have detected a reduction in peritonitis of
30%). However, looking at Figure 3, it is difficult to suggest
there is even a trend toward a prolonged peritonitis-free
survival in the patients using biocompatible solutions.
Our current study has important limitations that were
discussed by Locatelli and La Milia.22 We acknowledge that our
study was not blinded and that treatment bias based on the PD
solutions was possible. Our study also compared solutions
from two different providers, thereby introducing further
confounding factors such as ‘connectology’ and other subtle
differences in PD solution/packaging. This would have
increased the statistical noise, reducing the power of the study
to detect small differences in peritonitis rates. However,o15%
of patients enrolled in this study received fluids from Fresenius
Medical Care (the remaining patients were all provided PD
solutions by Baxter Healthcare). Even when the data were
reanalyzed to include only ‘Baxter’ patients, there were still no
statistically significant differences in peritonitis rates.
Our results are again disappointing for clinicians who had
hoped that the use of biocompatible solutions would herald an
important advance in the treatment of PD patients. Benefits of
biocompatible solutions have been demonstrated in vitro on
peritoneal cells, including neutrophil function23 and mesothe-
lial cell viability.5,24 In addition, there are human adult25,26 and
children27 studies, as well as an in vivo animal study,3 that have
demonstrated increased Ca125 levels (a marker of mesothelial
cell mass) with the use of biocompatible solutions. However, it
remains to be proven whether these effects will translate into
benefit for the patients in real-life when other factors such as
low-grade infection/catheter colonization, technique burn-out
may be more dominant determinants of the success of PD for
the individual.
PD solutions that are biocompatible are more expensive,
and in an era of financial restraint around the world the cost
benefit of biocompatible solutions should be addressed more
openly. Randomized controlled trials have failed to conclu-
sively demonstrate advantages of biocompatible solutions on
residual renal function, although we await the results of a
meta-analysis currently being undertaken by the Cochrane
Renal Group (protocol published by Wiggins et al.28). We
hope that authors of other randomized controlled studies in
this field can also present their long-term follow-up data for
peritonitis. Accumulation of such data will help to determine
whether these biocompatible solutions have a clinical
advantage in ‘real-life’ scenarios.
MATERIALS AND METHODS
The study was approved by the East London and The City Research
Ethics Committee. We recruited incident patients starting PD at our
unit between 1 January 2004 and 1 June 2008. During this recruitment
period, our PD program contracted slightly from 230 patients at any
one time to 200. Approximately 60% of all our patients are established
on CAPD, and the systems used during the study period were UV
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Compact (Baxter Healthcare, 15%); MiniSolo (Baxter Healthcare,
70%); or StaySafe (Fresenius Medical Care, 15%). Patients undergoing
APD used the HomeChoice (Baxter Healthcare) machine (as Fresenius
Sleep Safe was not available in our Unit at the time of recruitment).
Physioneal solutions (Baxter Healthcare) are not available for the UV
Flash Compact system (Baxter Healthcare), and thus patients who
were thought to be most suited to this system were excluded from
recruitment.
Patients who consented were randomized to standard solution
(Dianeal or StaySafe standard depending on the connectology that
was thought to be best suited to the individual) or the equivalent
biocompatible solution (Physioneal or Balance), and were trained
to perform CAPD or APD by the same team of nursing staff.
Icodextrin (Extraneal, Baxter Healthcare) and Nutrineal (Baxter
Healthcare) were freely available for use for both groups of patients
using Baxter connectology; 82.6% of prevalent patients in our unit
are using Extraneal (72.9% CAPD and 94.1% APD). Although
amino-acid-based solution (Nutrineal) was available for all patients
on the Baxter systems, it was prescribed infrequently (o5%).
Baseline clinical data were recorded by patient chart review.
These included age, sex, ethnicity, underlying renal disease, and PD
regimen (CAPD vs APD).
Diagnosis of peritonitis
Diagnosis of peritonitis was made in accordance with ISPD
guidelines.29 Effluent was obtained from CAPD and APD patients
after a minimum of 2 h dwell. Samples were sent immediately for
microbiological assessment that included Gram stain, microscopy
for cell count, and culture on blood and MacConkey agar in CO2 at
37 1C for 48 h. Two 10ml samples were also inoculated into aerobic
and anerobic blood culture broth (BacT/ALERT Biomerieux,
Durham, NC). This was continually monitored for bacterial growth
using the automated BacT/Alert system for 4 days.
Statistics
At the time this study was planned, registry data from Baxter
suggested that biocompatible solutions might halve the peritonitis
rate. We therefore powered the recruitment to detect a hazard ratio
of developing peritonitis (peritonitis-free survival) of 0.5 in favor
of biocompatible solutions. We assumed that accrual period would
be 24 months, the follow-up period would be 24 months, and the
median peritonitis-free survival would be 24 months (historical
audits from our unit suggested an expected peritonitis rate of 1:24
patient-months). On the basis of these assumptions, 170 patients
were calculated to be required in order to detect the expected
treatment difference at a two-sided 5.0% significance level with a
probability of 90%.
Kaplan–Meier PD technique survival curve was plotted with
censoring for transplantation and transfer of patient to other units
and repeated with additional censoring for death on PD. Peritonitis
data analysis was performed in two ways:
K Peritonitis-free survival curves were plotted and hazard ratios
were calculated using the log-rank Mantel–Cox test.
K Absolute peritonitis rates were compared using Pearson
uncorrected w2.
DISCLOSURE
The Renal Unit at Barts and The London NHS Trust has received
research and unrestricted educational grants from Baxter Healthcare
and Fresenius Medical Care. SL-SF has also received honoraria for
lectures from Baxter Healthcare and Fresenius Medical Care.
REFERENCES
1. Davies SJ. Preserving residual renal function in peritoneal dialysis:
volume or biocompatibility? Nephrol Dial Transplant 2009; 24:
2620–2622.
2. Devuyst O, Topley N, Williams JD. Morphological and functional changes
in the dialysed peritoneal cavity: impact of more biocompatible solutions.
Nephrol Dial Transplant 2002; 17(Suppl 3): S12–S15.
3. Park MS, Kim JK, Holmes C et al. Effects of bicarbonate/lactate solution on
peritoneal advanced glycosylation end-product accumulation. Perit Dial
Int 2000; 20(Suppl 5): S33–S38.
4. Boulanger E, Wautier MP, Gane P et al. The triggering of human
peritoneal mesothelial cell apoptosis and oncosis by glucose and
glycoxydation products. Nephrol Dial Transplant 2004; 19: 2208–2216.
5. Ha H, Yu MR, Choi HN et al. Effects of conventional and new peritoneal
dialysis solutions on human peritoneal mesothelial cell viability and
proliferation. Perit Dial Int 2000; 20(Suppl 5): S10–S18.
6. Sundaram S, Cendoroglo M, Cooker LA et al. Effect of two-chambered
bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral
blood mononuclear cell and polymorphonuclear cell function in vitro.
Am J Kidney Dis 1997; 30: 680–689.
7. Ahmad S, Sehmi JS, Ahmad-Zakhi KH et al. Impact of new dialysis
solutions on peritonitis rates. Kidney int Suppl 2006; (103): S63–S66.
8. Furkert J, Zeier M, Schwenger V. Effects of peritoneal dialysis solutions
low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 2008;
28: 637–640.
9. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous
ambulatory peritoneal dialysis patients treated with a peritoneal dialysis
fluid with neutral pH and low glucose degradation product concentration
(Balance). Perit Dial Int 2005; 25: 248–255.
10. Fan SLS, Pile T, Punzalan S et al. Randomized controlled study of
biocompatible peritoneal dialysis solutions: effect on residual renal
function. Kidney Int 2007; 73: 200–206.
11. Skoufos L, Topley N, Cooker L et al. The in vitro biocompatibility
performance of a 25mmol/L bicarbonate/10mmol/L lactate-buffered
peritoneal dialysis fluid. Kidney int Suppl 2003; (88): S94–S99.
12. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal
dialysis solution—clinical benefits. The Bicarbonate/Lactate Study Group.
Perit Dial Int 2000; 20: 516–523.
13. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a
new biocompatible peritoneal dialysis fluid (balance) on the peritoneal
membrane. Kidney Int 2004; 66: 408–418.
14. le Poole CY, Welten AG, Weijmer MC et al. Initiating CAPD with a regimen
low in glucose and glucose degradation products, with icodextrin and
amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005; 25: S64–S68.
15. Montenegro J, Saracho RM, Martinez IM et al. Long-term clinical
experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial
Int 2006; 26: 89–94.
16. Szeto C-C, Chow K-M, Lam CW-K et al. Clinical biocompatibility of a
neutral peritoneal dialysis solution with minimal glucose-degradation
products—a 1-year randomized control trial. Nephrol Dial Transplant
2007; 22: 552–559.
17. Choi HY, Kim DK, Lee TH et al. The clinical usefulness of peritoneal dialysis
fluids with neutral pH and low glucose degradation product
concentration: an open randomized prospective trial. Perit Dial Int 2008;
28: 174–182.
18. Kim S, Oh J, Kim S et al. Benefits of biocompatible PD fluid for
preservation of residual renal function in incident CAPD patients: a 1-year
study. Nephrol Dial Transplant 2009; 24: 2899–2908.
19. Weiss L, Stegmayr B, Malmsten G et al. Biocompatibility and tolerability of
a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int
2009; 29: 647–655.
20. Haag-Weber M, Kramer R, Haake R et al. Low-GDP fluid (Gambrosol trio)
attenuates decline of residual renal function in PD patients: a prospective
randomized study. Nephrol Dial Transplant 2010; 25: 2288–2296.
21. Lee HY, Choi HY, Park HC et al. Changing prescribing practice in CAPD
patients in Korea: increased utilization of low GDP solutions improves
patient outcome. Nephrol Dial Transplant 2006; 21: 2893–2899.
22. Locatelli F, La Milia V. Preservation of residual renal function in peritoneal
dialysis patients: still a dream? Kidney Int 2008; 73: 143–145.
23. Mackenzie R, Holmes CJ, Jones S et al. Clinical indices of in vivo
biocompatibility: the role of ex vivo cell function studies and effluent
markers in peritoneal dialysis patients. Kidney Int Suppl 2003; 88:
S84–S93.
24. Jorres A, Bender TO, Finn A et al. Biocompatibility and buffers: effect of
bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function.
Kidney Int 1998; 54: 2184–2193.
990 Kidney International (2011) 80, 986–991
or ig ina l a r t i c l e S Srivastava et al.: Biocompatible PD solutions and peritonitis
25. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a
peritoneal dialysis fluid with less glucose degradation products. Kidney Int
2001; 59: 348–357.
26. Simonsen O, Wieslander A, Landgren C et al. Less infusion pain and
elevated level of cancer antigen 125 by the use of a new and more
biocompatible PD fluid. Adv Perit Dial 1996; 12: 156–160.
27. Haas S, Schmitt CP, Arbeiter K et al. Improved acidosis correction and
recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis
solution among children undergoing automated peritoneal dialysis.
J Am Soc Nephrol 2003; 14: 2632–2638.
28. Wiggins KJ, Strippoli GF, Craig JC et al. Biocompatible dialysis
fluids for peritoneal dialysis. Cochrane Database Syst Rev 2009:
CD007554.
29. Piraino B, Bailie GR, Bernardini J et al. Peritoneal dialysis-related
infections recommendations: 2005 update. Perit Dial Int 2005; 25:
107–131.
Kidney International (2011) 80, 986–991 991
S Srivastava et al.: Biocompatible PD solutions and peritonitis o r ig ina l a r t i c l e
